Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Still can't believe

<< Previous

Bullboard Posts

Next >>

Comment by Layth1990on Jan 12, 2021 4:50pm

267 Views

Post# 32278760

RE:RE:RE:Still can't believe

I have no idea but i'm optimistic. My mind telling me this will explode all of a second. big pharma for partnering, That will push the price to 6 then followed by nasdaq listing. we will sit around 8cad before phase 3 and 12 during phase 3. If Results are successfull, we wont even have a chance to check it out ,we get bought around 50cad/share.

it is worth the wait! I have ate in my tfsa, rrap and private investing. I invested all my saving in this. We will make money for sure. Imagine phase 2 we hit 8.9cad. Eventually phase 3 will start and sp will hit more than that.

<< Previous

Bullboard Posts

Next >>

Gold, growth and sustainability in focus for Mandalay Resources